Navigation Links
CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
Date:8/19/2008

VIENNA, Va., Aug. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) announced today that it has entered into an exclusive licensing agreement with Teva Pharmaceutical Industries Ltd. (Teva), a leading global pharmaceutical company, under which CEL-SCI has granted Teva an exclusive license to market and distribute the Company's cancer drug Multikine for Israel and Turkey (the "Territory"). The licensing agreement is initially restricted to the areas of head and neck cancer. Teva has the right, subject to certain conditions, to extend the licensing agreement to include other cancers during the term of this agreement. Multikine is currently thought to be potentially useful in treating many tumor types.

Pursuant to the agreement, Teva will participate in CEL-SCI's upcoming global Phase III clinical trial. Teva will fund a portion of the Phase III clinical study and Teva's clinical group will conduct part of the clinical study in Israel under the auspices of CEL-SCI and its Clinical Research Organization. Teva will also be responsible for registering the product in the Territory. Once Multikine has been approved, CEL-SCI will be responsible for manufacturing the product, while Teva will be responsible for sales in the Territory. Revenues will be split 50/50 between CEL-SCI and Teva.

"We believe that Teva's expertise and knowledge in successfully conducting large pivotal clinical trials and in developing markets for large unmet medical needs will prove invaluable in maximizing Multikine's potential. This agreement is consistent with our strategy to share the clinical and regulatory expenses associated with the development of Multikine while retaining rights to market Multikine in North America and Europe," said Geert Ker
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PA (PRWEB) November 25, 2014 The ... of its official conference and exposition mobile app, ... for free download in the App Store for iOS ... a valuable resource tool before, during and after the ... containing details on exhibiting companies, technical sessions, Conferee Networking ...
(Date:11/26/2014)... and WILMINGTON, DE (PRWEB) November 26, 2014 ... Annual MPN Heroes recognition reception on December 5, 2014, ... Hematology’s annual meeting. The MPN Heroes event will honor ... in the field of myeloproliferative neoplasms (MPNs). , ... "Nashville," will discuss his family's cancer journey at the ...
(Date:11/26/2014)... , 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia ... mercato europeo in occasione di Hi Europe 2014 (dal ... Si tratta della curcumina con la maggiore ... (senza cristalli) e ingredienti approvati dalle norme europee. ... spezia della pianta curcumina ( Curcuma longa ) che ...
(Date:11/24/2014)... , Nov. 24, 2014  Last week, ... G.K. Butterfield (D-NC) took a bold bipartisan ... by introducing the OPEN Act. Original co-sponsors of ... (D-FL). The Act will incentivize drug makers and ... rare diseases and pediatric cancers, which opens the ...
Breaking Biology Technology:Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... July 14 EnVivo Pharmaceuticals today announced at the Alzheimer,s ... of behavioral deficits observed in an Alzheimer,s disease transgenic animal ... (GSM). The data was disclosed as part of the preclinical ... , EVP-0962 is a proprietary small ...
... 14 Bio-Optronics, Inc., a leader in healthcare workflow software, ... solution that can simultaneously handle the most intricate scheduling policies, ... schedules. , , Physician and ... , Bio-Optronics President & CEO, Dan ...
... July 14 Environmental Tectonics Corporation,s (OTC Bulletin Board: ETCC) ... with Life Support Technologies (LST), a wound care management group ... two BARA-MED((R)) XD monoplace hyperbaric chambers in Hudson Valley Hospital, ... To date LST has purchased from ETC and ...
Cached Biology Technology:EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator 2NEW Momentum(TM) Physician and Staff Scheduling Software for Imaging Centers, OB/GYN, and Other Specialty Practices Improves Productivity and Equity in Scheduling 2Environmental Tectonics Corporation Announces Sale of Additional Monoplace Hyperbaric Chambers 2Environmental Tectonics Corporation Announces Sale of Additional Monoplace Hyperbaric Chambers 3Environmental Tectonics Corporation Announces Sale of Additional Monoplace Hyperbaric Chambers 4
(Date:11/4/2014)... In nature, the right amount of death at the ... density, according to new research that could help in ... wildlife stocks. , In a paper in the journal ... University researcher and European colleagues conclude that the kind ... a loss of individuals, or mortality, depends on the ...
(Date:11/4/2014)... --   3D scanner developer ... Fuel3D , a developer of 3D scanning solutions, today ... million (£4 million). This funding builds on the company,s initial ... paves the way for the commercial launch of the company,s ... was led by Chimera Partners and will be used to ...
(Date:11/3/2014)... published in this month,s Proceedings of the ... a recently discovered communication molecule of the body,s immune ... to limit inflammation and the current study reports its ... ability of the immune system to recognize and target ... effect on the immune system now allows us to ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... NEW YORK, NY (January 5, 2009) The copper ... question: Can copper and copper alloys (brass and bronze) ... infection? Results of laboratory testing and clinical trials indicate ... their work at the first world congress, ,Copper and ...
... of disease during pregnancy, mothers produce less aggressive ... The University of Nottingham have discovered. The ... effect on immune response based on environmental cues ... the immediate environment potentially determining offspring disease resistance ...
... NY, January 5, 2009Theodosius Dobzhansky, the late great geneticist ... makes sense except in the light of evolution." ... (February 12, 1809) and the 150th anniversary of the ... the theory of evolution by means of natural selection ...
Cached Biology News:International copper industry defines role in the fight against hospital infections 2Mothers pass on disease clues to offspring 2GEN joins Charles Darwin 2009 celebration 2
... and regulate cell stretching or compression of ... stage. Computer controlled so you can precisely ... strain to produce 64 unique strain parameters. ... the ST-150. Both models are compatible with ...
... Todays research and biologic production demands on ... to confirming viable cell populations. Therefore, both ... must be determined accurately and precisely. The ... automatic and cost effective means to perform ...
... Precipitation Kit is designed for concentration ... aqueous samples. Proteomics sample analysis is ... non-protein impurities such as buffers, salts ... that interfere with electrophoretic separations or ...
... The LS series of laser scanners ... Gene Expression Suite solution. ,Gene expression ... other requirements essential to the advancement ... giving rise to novel microarray formats and ...
Biology Products: